ARCHIVES

Competing Strategies For Breast Cancer? Brinker Tries to Ensure acceptance Of Report, Visco Urges Broad Effort

This article is from The Cancer Letter archive.

Vol. 19 No. 39 | October 8, 1993

Download PDF Visit The Full Archive

Related Articles

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

NCI Advises Five-Year Limit On Tamoxifen Use, in Letter To Doctors

December 8, 1995

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

February 17, 2006

New Criteria For Comprehensive center Status finalized

November 17, 1989

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996

FDA Approves Tamoxifen For “Reduction In Incidence,” Avoids Word “Prevention”

November 6, 1998